David R Jones M.D.,P.A.

David R Jones M.D.,P.A. was paid $63K by Medicaid between Apr 2019 and Apr 2024, across 31 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 40% of everything it billed.

Compared with peers

Next to other Pain Medicine (Anesthesiology) Physician providers in Texas

Rank by total paid#16 of 64

Median peer was paid$7K

This provider vs. median9.7×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	687	$24.81
2020	7,293	$12K
2021	6,396	$41K
2022	3,614	$6K
2023	1,433	$4K
2024incomplete	115	$1K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	40%	994	964	$26K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	39%	1,947	1,762	$25K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	14%	1,438	1,378	$9K
G0396	Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes	4.2%	1,599	1,508	$3K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	1.6%	180	173	$1K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	143	136	$480.60
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	109	108	$263.08
G8950	Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented	0%	802	727	$0.00
G9903	Patient screened for tobacco use and identified as a tobacco non-user	0%	822	731	$0.00
G9906	Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy)	0%	610	557	$0.00
G8510	Screening for depression is documented as negative, a follow-up plan is not required	0%	131	125	$0.00
1036F		0%	923	822	$0.00

19 more codes

G9902	Patient screened for tobacco use and identified as a tobacco user	0%	604	$0.00
G8420	Bmi is documented within normal parameters and no follow-up plan is required	0%	305	$0.00
G9583	Patients prescribed opiates for longer than six weeks	0%	566	$0.00
G2197	Patient screened for unhealthy alcohol use using a systematic screening method and not identified as an unhealthy alcohol user	0%	21	$0.00
G8418	Bmi is documented below normal parameters and a follow-up plan is documented	0%	12	$0.00
1123F		0%	32	$0.00
4004F		0%	553	$0.00
1124F		0%	985	$0.00
G9578	Documentation of signed opioid treatment agreement at least once during opioid therapy	0%	821	$0.00
G8417	Bmi is documented above normal parameters and a follow-up plan is documented	0%	1,045	$0.00
G8427	Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications	0%	1,997	$0.00
G8783	Normal blood pressure reading documented, follow-up not required	0%	165	$0.00
G9622	Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method	0%	880	$0.00
G9577	Patients prescribed opiates for longer than six weeks	0%	795	$0.00
G0444	Annual depression screening, 5 to 15 minutes	0%	119	$0.00
G8730	Pain assessment documented as positive using a standardized tool and a follow-up plan is documented	0%	597	$0.00
G9584	Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy	0%	313	$0.00
G0030	Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user	0%	12	$0.00
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	0%	18	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLINSCOMB, ALISA (OFFICE/BILLING MANAGER)